
|Articles|May 13, 2004
Drug treats PCa patients with bone metastases
Novartis offers zoledronic acid injection (ZOMETA) for the treatmentof patients with documented bone metastases from solid tumors, includingprostate cancer, in conjunction with standard antineoplastic therapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5





